Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Journal of Geriatric Oncology|March 7, 2026
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailtyPatrick M Reagan, Allison Magnuson, Craig A Portell, et al.
Blood Advances|October 26, 2021
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphomaCraig A Portell, Nolan A Wages, Brad S Kahl, et al.
Blood Cancer Journal|May 12, 2025
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403Craig A Portell, Opeyemi A Jegede, Nina Wagner-Johnston, et al.
Leukemia|February 12, 2026
Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphomaJing Gao, Xiaohong Zhao, Qing Yin, et al.
Blood Advances|August 25, 2021
Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLLKallesh D Jayappa, Vicki L Gordon, Christopher G Morris, et al.
Blood Advances|October 17, 2017
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCLKallesh D Jayappa, Craig A Portell, Vicki L Gordon, et al.
The Journal of Clinical Investigation|May 11, 2023
PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosisKallesh D Jayappa, Brian Tran, Vicki L Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell LymphomaNancy L Bartlett, Uwe Hahn, Won-Seog Kim, et al.
Blood Cancer Discovery|November 20, 2023
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Saran Vardhanabhuti, Miguel A Canales, et al.
Blood Advances|February 22, 2023
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphomaYazeed Sawalha, Subir Goyal, Jeffrey M Switchenko, et al.
Pageof 5